Physician profile
Golshan Fahimi
NPI 1376066548
$2,570.58
in general payments reported to CMS, 2019-2025
17 companies · $2,028 in 2025
The $2,028 reported for 2025 was more than what 76% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $132 · 2023: $184 · 2024: $227 · 2025: $2,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,438.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $373.67 | 2025 | Uplizna |
| Abbvie INC. | $370.35 | 2025 | |
| Lilly USA, LLC | $256.74 | 2025 | Kisunla, Zepbound, Amyvid |
| Tg Therapeutics, INC. | $242.87 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $226.68 | 2024 | Austedo Xr, Ajovy |
| Neurocrine Biosciences, INC. | $190.59 | 2022-2025 | |
| Pfizer INC. | $149.19 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $124.98 | 2023 | |
| Avadel Cns Pharmaceuticals, LLC | $124.88 | 2025 | Lumryz |
| Csl Behring | $124.88 | 2025 | Hizentra |
| Alexion Pharmaceuticals, INC. | $121.63 | 2025 | |
| Amneal Pharmaceuticals LLC | $118.96 | 2025 | Crexont |
| Janssen Biotech, INC. | $53.50 | 2022 | |
| Averitas Pharma INC. | $34.73 | 2023 | Qutenza |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.95 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $21.01 | 2022 | |
| Eisai INC. | $13.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Golshan Fahimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.